Skip to content

When you choose to publish with PLOS, your research makes an impact. Make your work accessible to all, without restrictions, and accelerate scientific discovery with options like preprints and published peer review that make your work more Open.


Restoring vision with a new optogenetic tool

Photoreceptor degeneration, and eventual blindness, affect millions worldwide. Image credit: flickr user Jenn Turner.
Photoreceptor degeneration, and eventual blindness, affect millions worldwide. Image credit: flickr user Jenn Turner.

Millions of people worldwide suffer from progressive degeneration of the eye’s photoreceptors (the light-sensing cells), leading ultimately to blindness. A recent therapeutic approach for restoring vision in blind retinas involves introducing light-sensing proteins into surviving retinal cells that normally cannot sense light, turning them into “replacement photoreceptors”. This so-called “optogenetic” method, however, has several limitations, because traditional light-sensitive proteins require extremely high light intensities, which can be harmful, and use a mechanism alien to the cells.


In a new PLOS Biology paper, Michiel van Wyk, Sonja Kleinlogel and their colleagues bring this promising technology closer to medical application by engineering a new light-sensing protein that is compatible with the cells’ own signalling mechanism but retains all the advantages of traditional optogenetic proteins: fast responsiveness and resistance to light damage (“bleaching”).


Design of Opto-mGluR6. Image credit: doi: 10.1371/journal.pbio.1002143
Design of Opto-mGluR6. Image credit: doi:10.1371/journal.pbio.1002143

This new protein, termed Opto-mGluR6, is a chimeric protein that consists of two “local” retinal proteins: the light-sensing domains of the retinal photopigment melanopsin and the signaling domain of the metabotropic glutamate receptor 6 (mGluR6). mGluR6 is a protein found in retinal ON-bipolar cells that is naturally activated by the neurotransmitter glutamate released from the photoreceptors, thereby amplifying the incoming signal.


Because ON-bipolar cells naturally receive direct input from the photoreceptors, turning the native chemically activated receptor mGluR6 into a light-activated receptor means that signaling mechanisms in the ON-bipolar cells are preserved, conferring high light-sensitivity and fast “normal” responsiveness. And using the extracellular domain of melanopsin as a “light antenna” provides resistance to bleaching: No matter how hard the protein is hit by light, the response of Opto-mGluR6 never attenuates.


To demonstrate the therapeutic potential of this new tool, the authors show that mice suffering from retinitis pigmentosa – a genetic form of retinal degeneration characterized by night blindness and progressive loss of peripheral vision – can be treated to regain daylight vision.


This new optogenetic approach could potentially be applied to the treatment of any kind of photoreceptor degeneration, including age-related macular degeneration.  Plus, the engineering of the bleach-resistant chimeric Opto-mGluR6 opens up broader possibilities for the treatment of other conditions: The mGluR6 receptor belongs to a large family of diverse signaling proteins called G-protein-coupled transmembrane receptors, which are implicated in a wide range of human disorders and are consequently prime targets for biomedical research and pharmaceutical interventions.


Leave a Reply

Your email address will not be published. Required fields are marked *

Add your ORCID here. (e.g. 0000-0002-7299-680X)

Back to top